No Data
RBC Capital Maintains Applied Therapeutics(APLT.US) With Buy Rating, Maintains Target Price $12
RBC Capital analyst Brian Abrahams maintains $Applied Therapeutics(APLT.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 51.1
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Applied Therapeutics (APLT) and Oric Pharmaceuticals (ORIC)
RBC Capital Reiterates Outperform on Applied Therapeutics, Maintains $12 Price Target
Applied Therapeutics Analyst Ratings
CrossFirst Bankshares Posts Q2 Earnings, Joins Owens & Minor, Reddit And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Applied Therapeutics Added to Russell 3000 Index
No Data